AstraZeneca shares rise after Phase 3 Tagrisso win
AstraZeneca (NYSE:AZN) priced its stock at $161.62 after reporting another Phase 3 victory Tuesday, saying Tagrisso plus Orpathys from Hutchmed delayed disease progression versus Tagrisso alone in previously untreated patients.